What is the purpose of issuing these senior notes?

The company intends to use the net proceeds from the issuance of these senior notes for general corporate purposes, which includes repaying outstanding amounts under its revolving credit facility. This suggests a move to refinance short-term debt with longer-term, fixed-rate financing.

What are the key terms of the senior notes?

The notes are issued in two series: $75 million of 3.94% Series A Senior Notes due December 11, 2023, and $75 million of 4.04% Series B Senior Notes due December 11, 2025. Both are fixed-rate debt instruments. Prepayment is possible under specific conditions, and accelerated repayment may be required in the event of a change of control or certain asset sales.

Who guarantees these notes, and what does that mean for investors?

The senior notes are unconditionally guaranteed by four major subsidiaries: IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc., and OPTI Medical Systems, Inc. This guarantee enhances the security for the noteholders by providing recourse to these subsidiaries' assets and financial standing in addition to the parent company.

What kind of covenants are in place for these notes?

The agreement includes standard covenants, such as restrictions on liens, subsidiary indebtedness, fundamental changes, investments, and affiliate transactions. A key financial covenant is a consolidated leverage ratio test. These covenants are designed to protect the noteholders by limiting the company's financial risk-taking and ensuring it maintains a certain financial health.

IDXX 8-K: Material Agreements & Financial Events

Summary

IDEXX LABORATORIES, INC. (IDXX) filed an 8-K on December 11, 2013, to report the issuance and sale of $150 million in senior notes through a private placement. This offering comprises $75 million of 3.94% Series A Senior Notes due in 2023 and $75 million of 4.04% Series B Senior Notes due in 2025. The company intends to use the net proceeds for general corporate purposes, including the repayment of outstanding amounts under its revolving credit facility. This private placement represents a significant financing activity for IDXX. The terms include fixed interest rates and specific maturity dates, with provisions for prepayment and acceleration under certain conditions, such as a change of control or default events. The notes are unconditionally guaranteed by several of the company's subsidiaries, providing an additional layer of security for the noteholders and indicating strong internal financial backing. Investors should note the company's proactive approach to managing its capital structure and funding needs.

Key Highlights

1IDXX issued $150 million in senior notes through a private placement on December 11, 2013.
2The offering consists of two tranches: $75 million of 3.94% Series A Senior Notes due December 11, 2023, and $75 million of 4.04% Series B Senior Notes due December 11, 2025.
3Proceeds will be used for general corporate purposes, including repaying outstanding amounts on its revolving credit facility.
4The senior notes are fixed-rate debt, offering predictability in interest expense.
5Prepayment options are available for the company, subject to make-whole provisions, and mandatory prepayment can be triggered by a change in control or certain asset dispositions.
6The obligations are unconditionally guaranteed by four key subsidiaries: IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc., and OPTI Medical Systems, Inc.
7The Note Purchase Agreement includes customary affirmative, negative, and financial covenants, including a consolidated leverage ratio test, and restricts certain activities like incurring additional subsidiary indebtedness or making certain investments.

IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Dec 12, 2013)

Summary

Key Highlights

Frequently Asked Questions